Altus Pharmaceuticals Appoints Renato Fuchs, Ph.D., Senior Vice President, Manufacturing and Technical Operations.CAMBRIDGE, Mass. -- Altus Pharmaceuticals Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ALTU), a biopharmaceutical company developing and commercializing oral and injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today that Renato Fuchs, Ph.D., has been appointed Senior Vice President, Manufacturing and Technical Operations. In this role, Dr. Fuchs will oversee all aspects of manufacturing operations Manufacturing operations concern the operation of a facility, as opposed to maintenance, supply and distribution, health, and safety, emergency response, human resources, security, information technology and other infrastructural support organizations. as the Company continues to advance its two lead product candidates, ALTU-135 and ALTU-238, toward Phase III clinical development. "We could not be more pleased to have someone with Renato's expertise joining Altus at this time," said Sheldon Berkle, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Altus. "With over 30 years of experience in the biotechnology and pharmaceutical industries, Renato has an incredibly broad and proven track record in process development, scale-up, manufacturing and registration of biopharmaceutical products in both the U.S. and Europe. We believe he will play a critical role in achieving our milestones as we work to advance our clinical programs forward towards commercialization." Dr. Fuchs recently served as Senior Vice President, Manufacturing and Operations at Shire HGT HGT Height HGT Harlem Globetrotters HGT Harmonic Greedy Triplets HGT Hudson Guild Theatre (New York, NY) HGT Hand Geometry Technology HGT High Grand Touring (previously Transkaryotic Therapies, Inc. / TKT TKT Ticket TKT Transketolase TKT Twisted Kaiju Theater (web forum) TKT T Kang Taekwondo (New York) TKT Thin Kerf Technologies ), where he was responsible for manufacturing, materials management, process development and engineering operations throughout the company's transition from a "research organization" to a fully integrated biotechnology company. Prior to his tenure at Shire HGT, Dr. Fuchs spent almost ten years at Chiron Corporation, where he was Senior Vice President BioPharma Operations and Process Development, responsible for the manufacturing, logistics, validation, QC, process development, materials management, QA and manufacturing business development for therapeutic products and vaccines, and then Senior Vice President BioPharmaceuticals, responsible for overseeing and coordinating critical domestic and international projects including the management of external collaborations. Previously in his career, Dr. Fuchs has also held the positions of Vice President and then Senior Vice President of Pharmaceutical Development at Centocor, Inc., and, during his 15 years at Schering-Plough Corporation, held positions of increasing responsibility, starting as a Senior Scientist - Bioengineer and ultimately becoming Senior Director, Biotechnology Process Development. Dr. Fuchs received a BS in Chemical Engineering from the Universidad del Valle The term Universidad del Valle could refer to the following:
About Altus Pharmaceuticals Inc. Altus Pharmaceuticals, headquartered in Cambridge, MA is a biopharmaceutical company focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. The Company's website is http://www.altus.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement Certain statements in this news release concerning Altus' business are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Altus might make or by known or unknown risks and uncertainties, including, but not limited to uncertainties as to the future success of ongoing and planned clinical trials; and the unproven safety and efficacy of products under development. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Altus' reports to the Securities and Exchange Commission, including its Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the fiscal year ended December 31, 2005. However, Altus undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion